NCT00136942已完成3 期
A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.21 个研究点 分布在 1 个国家目标入组 370 人开始时间: 2005年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 370
- 试验地点
- 21
- 主要终点
- The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
研究概览
简要总结
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
- •LDL-C < 6.0 mmol/l
- •Triglyceride level < 5.0 mmol/l.
排除标准
- •Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
结局指标
主要结局
The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
次要结局
- The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
研究者
研究点 (21)
Loading locations...
相似试验
已完成
4 期
nmet LDL-C target in very high risk cardiovascular patientsNL-OMON21157WC1,000
已完成
4 期
Prevalence of unmet target LDL-C recommendations in very high risk patients despite high intensity lipid modifying therapyHyperlipidaemia/ high cholesterol post myocardial infarction10003216NL-OMON55816WCN (Werkgroep Cardiologische centra Nederland)1,000
已完成
4 期
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High CholesterolDyslipidemiasNCT00645151Pfizer's Upjohn has merged with Mylan to form Viatris Inc.512
已完成
3 期
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary SyndromeAcute Coronary SyndromeNCT04873934Novartis Pharmaceuticals400
已完成
不适用
Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in KoreaDyslipidemiaNCT01372956AstraZeneca4,950